FOI_9202

Internal Reference Number: FOI_9202

Date Request Received: 02/02/2026 00:00:00

Date Request Replied To: 12/02/2026 00:00:00

This response was sent via: By Email

Request Summary: Biologics Medicines in Gastroenterology

Request Category: Companies


Question Number 1: . How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Etrasimod • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Mirikizumab • Ozanimod • Risankizumab • Tofacitinib • Upadacitinib • Ustekinumab - Stelara • Ustekinumab Biosimilar • Vedolizumab • Guselkumab

Answer To Question 1: Please see our response to all questions in the attached file. To accompany this answer to question 1 please also see the documents listed below: 13505 - FOI_9202 - Biologics Medicines in Gastroenterology - FOR ISSUE.xlsx

Question Number 2: If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Etrasimod • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Mirikizumab • Ozanimod • Risankizumab • Tofacitinib • Upadacitinib • Ustekinumab - Stelara • Ustekinumab Biosimilar • Vedolizumab • Guselkumab

Answer To Question 2: Please see our response to all questions in the attached file.
Please see Attachments:


To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.